Guan, Jun
Darb-Esfahani, Silvia
Richter, Rolf
Taube, Eliane T.
Ruscito, Ilary
Mahner, Sven
Woelber, Linn
Prieske, Katharina
Concin, Nicole
Vergote, Ignace
Van Nieuwenhuysen, Els
Achimas-Cadariu, Patriciu
Glajzer, Joanna
Woopen, Hannah
Stanske, Mandy
Kulbe, Hagen
Denkert, Carsten
Sehouli, Jalid
Braicu, Elena Ioana http://orcid.org/0000-0002-6930-4593
Article History
Received: 16 February 2019
Accepted: 22 February 2019
First Online: 27 February 2019
Compliance with ethical standards
:
: Dr. Elena Ioana reports grants, personal fees and other from Roche Pharma, personal fees from Clovis, personal fees and other from TesaroBio, personal fees and other from AstraZeneca, personal fees from Amgen, personal fees from Incyte, grants from Molecular Health, outside the submitted work; Dr. Sven Mahner reports research support, advisory board, honoraria and travel expenses from AstraZeneca, Bayer, Boehringer Ingelheim, Clovis, Eisai, GlaxoSmithKline, Jenapharm, Janssen-Cilag, Medac, MSD, Novartis, PharmaMar, Roche, Sensor Kinesis, Teva, Tesaro; Dr. Linn Woelber reports grants from medac oncology, during the conduct of the study; grants, personal fees and non-financial support from medac oncology, personal fees and non-financial support from Tesaro, personal fees from Roche, Pharmamar, Tewa, Astra Zeneca, Jenapharm and Janssen-Cilag, outside the submitted work; Dr. Carsten Denkert is the cofounder and shareholder of Sividon Diagnostics and in advisory board of Teva, Roche, AstraZeneca, Celgene, Pfizer, Novartis, Daiichi, and MSD. Other authors have no conflict of interest.